Introduction
Angiogenesis, the formation of new capillaries by budding from existing vessels, occurs in tumors and permits their growth, invasiveness, and metastasis (1, 2) . Pathological angiogenesis occurs in diseases such as cancer, rheumatoid arthritis, endometriosis and diabetic retinopathy (3, 4) .
Neo-angiogenesis is now considered essential for solid tumor growth and progression. Any significant increase in tumor mass beyond 2--3 mm must be preceded by an increase in the vascular supply to deliver nutrients and oxygen to the tumor cells and the neo-vascularization of endothelial cells (5) . Thus, angiogenesis inhibitors, which are not directly cytotoxic to tumor cells, can suppress tumor growth by inhibiting endothelial proliferation and migration and/or by inducing endothelial apoptosis in the vascular bed of tumors (6) .
Cyclooxygenase-2 (COX-2) has been implicated in tumor growth, metastasis and angiogenesis (7) , and is closely correlated with the microvessel density within tumors grown in animals (8, 9) . However, the adverse effects of synthetic COX-2 inhibitors Vioxx and celebrex have received much publicity, lately, and highlight the need for novel COX-2 inhibitors with less side effects for cancer prevention use.
Recently agents that inhibit angiogenesis and COX-2 have been identified from plants, with little side effects. Medicinal plants with anticancer activity have long been used for the treatment or prevention of various human disorders in folk medicine (10) . Among biologically active phytochemicals, tannins and polyphenolic compounds have been in the spotlight with preventive effects for heart disease (11), chronic inflammation (12) and cancer (13) .
By activity-guided fractionation, we isolated 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) from Galla Rhois, gallnut of Rhus chinensis MILL used for the treatment of thrombosis and cancer in Oriental medicine (14) . Recently, PGG was reported to inhibit in vitro capillary differentiation (tube formation) in endothelial cells (15) , interleukin-8 gene expression in U937 cells (16) , the proliferation of SK-HEP-1 cells (17) , and the expression of inducible nitric oxide synthase and production of prostaglandin E 2 (PGE 2 ) in Raw 264.7 cells (18) . It was also reported to protect rat neuronal cells from oxidative damage (19) . However, the in vivo antiangiogenic and anticancer activities of PGG and its underlying mechanisms still remain unclear, despite substantial in vitro data. This prompted us to evaluate the in vivo as well as in vitro antiangiogenic and anticancer activities of PGG and to elucidate its molecular mechanisms with special focus on COX-2 and MAPK pathways in human umbilical vein endothelial cells (HUVECs) and Lewis lung carcinoma (LLC) cells. With respect to COX-2 targeting actions, we used a known selective inhibitor, NS398, as a reference to compare the anti-angiogenic and antitumor efficacies and to compare and contrast mechanistic commonalities and differences.
Materials and methods
Isolation and identification of PGG from gallnut of Rhus chinensis MILL Gallnut of Rhus chinensis MILL was obtained from the Oriental Medical Hospital of Kyunghee University in Seoul, and kindly authenticated by Professor Nam-In Baek of Department of Oriental Herbal Materials, Kyunghee University. The methanol (MeOH) extract (252 g) was dissolved in distilled water (800 ml), and successively fractionated with equal volumes of n-hexane, ethyl acetate (EtOAc) and butanol with water. The butanol fraction (35 g), which was most effective in terms of antiangiogenic activity, was subject to silica gel column chromatography and eluted by chloroform, MeOH and H 2 O (65:35:10) and EtOAc, MeOH and H 2 O (100:15.6:13.5), followed by purification using HPLC (J'sphere ODS-HP80, 250 Â 20 mm ID, S-4 um, 80A, EtOAc:MeOH:H 2 O ¼ 6:3:1). The active compound was identified as PGG (MW ¼ 986) by NMR and FAB--MS analysis ( Figure 1A ). The purity of PGG was estimated to be 498%.
Cell culture
HUVECs were isolated from fresh human umbilical cord veins by collagenase treatment as described previously (20) . The cells were cultured in M199 (Invitrogen, Carlsbad, CA) supplemented with 20% fetal bovine serum (FBS), 3 ng/ml basic fibroblast growth factor (bFGF) (R&D Systems, Minneapolis, MN), 5 U/ml heparin and 100 U/ml antibiotic--antimycotic in 0.1% gelatin coated flasks. Mouse LLC cells were kindly provided by Dr Ikuo Saiki (Toyama Medical and Pharmaceutical Univ., Toyama, Japan) and cultured in EMEM (Invitrogen) supplemented with 10% FBS, 100 U/ml antibiotic--antimycotic and 2.2 g/l sodium bicarbonate. All cells were grown at 37 C in a humidified atmosphere containing 5% CO 2 .
Proliferation assay
Cell proliferation was determined using a 5-bromo-2 0 -deoxyuridine (BrdU) colorimetric assay kit (Roche, Sanhofer, Mannheim) according to the manufacturer's protocols. HUVECs (5 Â 10 3 cells/well) were seeded onto 0.1% gelatin coated 96-well plates and incubated in a humidified incubator for 24 h. After being starved for 6 h in M199 containing 5% heat-inactivated FBS, the cells were exposed to various concentrations of PGG (1, 5 and 10 mM) in the presence or absence of bFGF (10 ng/ml) incubated for 48 h at 37 C. Then, 10 ml of BrdU (100 mM) was added to each well, and the cells were further incubated for 6 h at 37 C. The cells were fixed and incubated with anti-BrdU and then detected by the substrate reaction. The reaction was stopped by the addition of 25 ml of 1 M H 2 SO 4 and the absorbance was measured using a microplate reader (Molecular Devices Co., USA) at 450 nm with 690 nm correction.
Tube formation assay
Tube formation assay was performed on Matrigel (Becton Dickinson Labware, Bedford, MA) as described previously (21) . Matrigel (250 ml) was added to 24-well plates and allowed to solidify for 1 h at 37 C. HUVECs (1 Â 10 5 cells/well) were treated with various concentrations of PGG (1, 5 and 10 mM) or NS398 (20, 40 and 80 mM) in the absence or presence of bFGF (10 ng/ml). After 18 h, randomly chosen fields were photographed under an Axiovert S 100 light microscope (Carl Zeiss, USA) at 100Â magnification. Tube network was quantified using NIH Scion image program.
Chorioallantoic membrane assay
The ex vivo angiogenic activity was assayed using chorioallantoic membrane (CAM) assay as described previously (22) . PGG (1 mg/egg) or NS398 (1.5 mg/egg) and bFGF (100 ng) were loaded onto one-fourth piece of thermonox disk (Nunc, Naperville, IL). The dried thermonox disk was applied to the CAM of a 10-day-old embryo. After a 72-h incubation, a fat emulsion was injected under the CAM for better visualization of the blood vessels. The number of newly formed blood vessels was counted. The experiment was repeated twice with 15 eggs for each group.
Matrigel plug assay
The Matrigel plug assay was performed as described previously (23) . Briefly, 6-week-old C57BL/6 mice (Daehan Biolink, Chungbuk) were given subcutaneous injection of 0.5 ml of growth factor reduced Matrigel containing PGG (80 mg) or NS398 (80 mg), bFGF (300 ng/mouse) and heparin (5 U). After 7 days, mice were killed, and the Matrigel plugs were removed. To quantify the formation of functional blood vessels, the amount of hemoglobin (Hb) was measured using the Drabkin reagent kit 525 (Sigma, St Louis, MO).
Tumor-induced angiogenesis LLC cells (5 Â 10 5 /50 ml) were intradermally inoculated on the back of 6-week-old C57BL/6 mice (Daehan Biolink). Three days later, PGG (4 and 20 mg/kg) or NS398 (4 mg/kg) were intraperitoneally administered for four consecutive days. Seven days after tumor inoculation, the mice were killed and the tumor-inoculated skin was separated from the underlying tissues. Tumorinduced angiogenensis was quantified by counting the newly formed blood vessels around LLC cells under a dissecting microscope.
Immunoassay for PGE 2 PGE 2 , a product of arachidonic acid by prostaglandin synthase COX-2, was determined using an enzyme linked immunosorbant assay kit (Cayman, Ann Arbor, MI) according to the manufacturer's protocol. HUVECs were starved for 6 h in M199 containing 5% FBS and then treated with bFGF (10 ng/ml) containing PGG (0.01, 0.1, 1 and 10 mM). After a 24-h culture, the cells were rinsed and incubated in Hanks' HEPES buffer with 50 mM arachidonic acid (Cayman) for 15 min at 37 C. The Hanks' HEPES buffer samples were collected in triplicate for the PGE 2 assay as described above.
Measurement of hVEGF
The level of hVEGF in the supernatant of HUVECs was measured with a commercially available ELISA kit (R&D systems, Minneapolis, MN). Briefly, HUVECs were starved for 6 h in M199 containing 5% FBS and then treated with bFGF (50 ng/ml) containing PGG (1, 5 and 10 mM). After a 48-h incubation, the supernatant was individually collected and measured by ELISA kit.
Western blotting
HUVECs exposed to various concentrations of PGG (1, 5, 10 and 20 mM) with or without bFGF (10 ng/ml) for 24 h were harvested and washed with cold PBS. The cells were incubated in lysis buffer (50 mM Tris--HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS and 1 mM EDTA), supplemented with protease inhibitors (10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin A and 1 mM of 4-(2-aminoethyl) benzenesulfonyl fluoride) and phosphatase 
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inhibitors (1 mM NaF and 1mM Na 3 VO 4 ) for 20 min on ice. Lysates were centrifuged at 14 000 g for 20 min at 4 C. The lysates containing 20 mg of protein were fractionated by SDS--PAGE and electrotransferred to a Hybond ECL transfer membrane (Amersham Pharmacia, Arlington Heights, IL). The blocked membranes were then immunoblotted with primary antibodies (1:1000 dilution) of COX-1 (Santa Cruz Biotechnology, Santa Cruz, CA), COX-2 (Becton Dickinson, Bedford, MA), VEGF (Santa Cruz Biotechnology), b-actin (Sigma), phospho-ERK-1/2, phospho-p38, phospho-JNK, ERK, p38, JNK (Cell Signaling Tech., Beverly, MA). The proteins were visualized using enhanced chemiluminescence.
Mouse tumor model LLC cells in subconfluent condition were harvested, resuspended in sterile PBS. LLC cells (2 Â 10 4 in 100 ml PBS) were subcutaneously injected into the right flank of C57BL/6 mice (Daehan Biolink). Three days after tumor inoculation, mice were given intraperitoneal injection of PGG (4 or 20 mg/kg) or NS398 (4 mg/kg) every other day. Tumor volumes were measured every 3 days with a caliper, and calculated according to the formula [(1 Â w 2 )/2], where l and w stand for length and width, respectively (24--26) . All mice were killed 18 days after tumor inoculation and the tumors were excised and weighed.
Immunohistochemistry Tumor specimens were immediately removed from killed mice and prepared for histological examination. Tumors were fixed overnight in 10% neutral buffered formalin, embedded in paraffin, and sectioned to 4 mm thickness. The tumor sections were immobilized and deparaffinized by immersing in xylene, dehydrated in a graded series of ethanol and washed with distilled water. For antigen retrieval, the tumor sections were boiled in 10 mM sodium citrate buffer (pH 6.0) for 10 min and cooled at room temperature. After washing with Tris Buffered Saline (TBS), endogenous peroxidase activity was blocked by incubation in 3% H 2 O 2 --methanol for 10 min at room temperature. The sections were stained for proliferating cell nuclear antigen (PCNA) (Dako A/S, Glostrup, Denmark), and von Willebrand factor (vWF) (Dako A/S), COX-1, COX-2 and VEGF antibodies overnight at 4 C using ABC and DAB kits (Vector Lab., Burlingame, CA) and counterstained with Mayer's hematoxylin solution (Sigma). Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was performed using a TdT-FragEL TM DNA fragmentation kit (Oncogene, Boston, MA) and counterstained with Mayer's hematoxylin solution. All stained sections were photographed under an Axiovert S 100 light microscope (Carl Zeiss) at 400Â magnification. J.-E.Huh et al.
Statistical analysis
All values represent means AE SD. The statistically significant differences between control and sample groups were calculated by the Student's t-test.
Results

PGG inhibits bFGF-induced proliferation and tube formation of HUVECs
To assess the antiangiogenic activity of PGG, its inhibitory effects on proliferation and tube formation in bFGF-treated HUVECs were examined. PGG significantly inhibited the proliferation of bFGF-treated HUVECs in a dose-dependent manner with IC 50 of 8 mM (Figure 2A ). This inhibitory effect was not due to cytotoxicity of PGG in HUVECs, because PGG did not show any significant cytotoxic effect on HUVECs up to 20 mM (data not shown). The IC 50 of cytotoxicity by PGG against HUVECs and LLC cells was over 75 mM (data not shown). Next, the effect of PGG and NS398 on capillary differentiation of HUVECs seeded on Matrigel was examined. PGG significantly reduced the formation of capillary-like structures in bFGF-stimulated HUVECs in a dose-dependent manner with IC 50 of~3 mM ( Figure 2B and C). In comparison, NS398 showed a moderate inhibitory effect on bFGF-induced tube formation of HUVECs with IC 50 of~50 mM ( Figure 2B and D).
PGG inhibits bFGF-induced angiogenesis in vivo
To evaluate the in vivo antiangiogenic activity of PGG and NS398, CAM and Matrigel plug assays were performed. PGG and NS398 significantly decreased the bFGF-induced vascularization in the CAMs at 1 and 1.5 mg/egg, respectively ( Figure 3 ). In Matrigel plug assay, bFGF-loaded plugs from mice exhibited a reddish color indicating abundant red blood cells and, therefore, hemoglobin in the newly formed vasculature, whereas a light yellowish color was shown in the PGG/bFGF-or NS398/bFGF-loaded plugs ( Figure 4A ). PGG and NS398 significantly reduced the hemoglobin content to 30 and 45% of untreated control, respectively, at a dose of 80 mg per plug ( Figure 4B ).
PGG suppresses tumor-induced angiogenesis in vivo
To assess the effect on the formation of new blood vessels induced by tumor cells (27) , LLC cells were intradermally inoculated on the back skin for tumor angiogenesis assay. As shown in Figure 4C and D, PGG and NS398 significantly reduced the number of vessels around LLC cells compared with untreated control.
PGG inhibits tumor growth in LLC-bearing mice PGG (4 and 20 mg/kg/day) or NS398 (4 mg/kg) were intraperitoneally administered on alternate days for 17 days from day 3 after subcutaneous inoculation with LLC on the flank region of the mice. PGG did not cause any significant body weight loss during the experiment (final body weight for the control group was 20.11 AE 1.34 g, and with 4 and 20 mg/kg PGG it was 19.49 AE 1.27 and 18.69 AE 1.21 g, respectively). PGG significantly inhibited tumor volume over time ( Figure 5A ) and also suppressed the tumor weight to 43 and 9% of PBS-treated control at 4 and 20 mg/kg, respectively ( Figure 5B PGG inhibition of angiogenesis through COX-2 and MAPK pathways proliferation ( Figure 6B ). PGG-treated tumors showed much decreased staining for vWF ( Figure 6C ), a marker of microvessel density, in comparison with PBS-treated control tumors. In contrast, PGG significantly increased the number of TUNEL positive tumor epithelial cells indicating apoptosis ( Figure 6D ).
PGG inhibits COX-2 and VEGF expression in the LLC tumor model
The expression of COX-1, COX-2, and VEGF in the LLC tumor model was examined by immunohistochemical analysis ( Figure 7A ). PGG treatment resulted in a significant decrease in the expression of COX-2 and VEGF ( Figure 7C and D) , while PGG did not affect the COX-1 expression in the LLC cells ( Figure 7B ). The selective COX-2 inhibitor NS398 also inhibited VEGF expression as well as COX-2 expression.
PGG downregulates COX-2 expression and reduces the levels of PGE 2 and VEGF in bFGF-induced HUVECs PGE 2 , a product of COX-2 and VEGF, has been linked to cancer (28, 29) . Therefore, the effects of PGG on COX-2 and VEGF expression were examined by western blotting. In addition, the levels of secreted PGE 2 and VEGF were measured by ELISA in bFGF-treated HUVECs. PGG downregulated COX-2 and VEGF expression without affecting COX-1 in bFGF-treated HUVECs ( Figure 8A ). Likewise, PGG significantly decreased the PGE 2 release and secreted VEGF level in a concentration-dependent manner compared with untreated control (Figure 8B and C). 
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PGG inhibits bFGF-induced angiogenesis via MAPKdependent pathway bFGF, a member of the heparin-binding multifunctional polypeptides, is one of the most potent angiogenic factors. It is also involved in proliferation and differentiation of a variety of normal and malignant cells and tissues (30, 31) . To understand the molecular mechanism by which PGG inhibits bFGFinduced angiogenesis, the potential involvement of MAPK pathway during antiangiogenic process by PGG was investigated by western blotting. PGG diminished the phosphorylation of extracellular signal regulated kinase (ERK) 1/2 in a dosedependent manner. Interestingly, PGG completely blocked bFGF-induced phosphorylation of phospho-Jun NH 2 -terminal kinase (JNK) at a concentration of 1 mM. On the contrary, PGG activated the expression of p38 MAPK in a concentration-dependent manner in bFGF-treated HUVECs ( Figure 9A ). The p38 specific inhibitor SB203580, which did not affect JNK and ERK ( Figure 9B ), effectively blocked the downregulation of COX-2 and VEGF and the antiproliferative activity induced by PGG in bFGF-treated HUVECs at nontoxic concentrations ( Figure 9C and D) . These results support a critical role of p38 MAPK pathway in inhibiting COX-2 and VEGF expression and angiogenesis.
Discussion
Angiogenesis plays a vital role in tumor growth, intravasation and metastasis (32, 35) . This process involves the proliferation, migration and tube formation of endothelial cells and can be initiated by angiogenic cytokines such as bFGF and VEGF (33) . Our data showed that PGG, one of the well-known gallotannin precursors (34) , significantly inhibited the proliferation and tube formation of bFGF-treated HUVECs with IC 50 of 8 mM. This result was similar to the in vitro antiangiogenic activity of PGG in VEGF-treated HUVECs (15) . PGG significantly inhibited the bFGF-stimulated capillary vessel formation in the CAM and also suppressed the vascularization in bFGF-treated Matrigel plugs in mice. These data support a potent antiangiogenic effect in vitro and in vivo. In addition, PGG suppressed LLC-induced angiogenesis without any adverse effect on body weight. The strong antiangiogenic activity of PGG predicts antitumor activity in vivo, which we demonstrated with LLC cells inoculated into the flank of C57BL/6 mice. PGG suppressed the growth of LLC tumors by 57 and 91% at 4 and 20 mg/kg, respectively. Immunohistochemical analysis has revealed the decreased microvessel density, reduced tumor cell proliferation (PCNA index) and increased tumor cell apoptosis from the excised tumor sections. While our data are consistent with the hypothesis that PGG can exert antitumor activity via a primary antiangiogenesis effect, leading to tumor cell growth inhibition and apoptosis, the experimental design did not exclude a direct apoptotic effect of PGG on tumor cells. There is ample PGG inhibition of angiogenesis through COX-2 and MAPK pathways evidence in the literature that the apoptosis of endothelial cells in the vascular bed of tumors precedes apoptosis of tumor cells indicating the close relationship between antiangiogenesis and tumor cell apoptosis (6) . Thus, additional works are required to sort out the cause--effect relationship between antiangiogenesis and tumor apoptogenic effects of PGG.
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Mechanistically, our work examined the role of COX-2 in PGG-induced antiangiogenic process. PGG significantly attenuated the expression of COX-2 and VEGF as well as decreased secretion of VEGF and PGE 2 in bFGF-treated HUVECs. COX-2 is known to be involved in tumor angiogenesis by promoting the expression of pro-angiogenic factors (36--38) . Hence, the decreased expression of COX-2 and VEGF found in tumor sections provided evidence that PGG is a COX-2 inhibitor with antiangiogenic activity in vivo. The COX-2 inhibitor NS398 significantly inhibited tube formation and neo-vascularization in CAM, much like another COX-2 inhibitor celecoxib (39) , supporting the important role of COX-2 pathway as a target in angiogenesis inhibition by PGG.
In our molecular work to identify the role of MAPK pathway, PGG diminished ERK 1/2, and JNK phosphorylation and increased phospho-p38 MAPK in a dose-dependent manner in bFGF-treated HUVECs. Our data showed that p38 MAPK inhibitor blocked the anti-proliferative activity and the decreased COX-2 and VEGF expression by PGG in bFGFstimulated HUVECs, supporting a critical role of p38 MAPK in the inhibition of COX-2 and angiogenesis by PGG with the other MAPK pathways also contributing to PGG-induced antiangiogenesis. Considering that p38 MAPK is generally activated by genotoxic agents or apoptosis (40) , activation of p38 MAPK by PGG may mediate the apoptosis of endothelial cells during antiangiogenic process. Thus, it will be necessary to study further the apoptotic mechanism of PGG in HUVECs and tumor cells.
In conclusion, these results demonstrate that PGG exerts anticancer activity chiefly via the inhibition of angiogenesis through COX-2 and MAPK-dependent pathways and suggest that PGG can be a novel non-toxic cancer chemopreventive agent.
